BIOCANCELL THERAPEUTICS INC.·4

Jan 5, 8:38 AM ET

NEVO DORON 4

4 · BIOCANCELL THERAPEUTICS INC. · Filed Jan 5, 2010

Insider Transaction Report

Form 4
Period: 2009-12-31
NEVO DORON
Director
Transactions
  • Award

    Option to Purchase Common Stock

    2009-12-31+20,00020,000 total
    Exp: 2019-12-31Common Stock, par value $0.01 (20,000 underlying)
Footnotes (3)
  • [F1]The exercise price is 3.17 NIS per share.
  • [F2]10,000 options shall vest and be exercisable on each of June 30, 2010 and December 31, 2010.
  • [F3]The Reporting Person holds an additional 40,000 options to purchase Common Stock, at an exercise price of $0.597 each.

Documents

1 file
  • 4
    doc1.xmlPrimary

    FORM 4